A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I

被引:235
|
作者
Wang, N [1 ]
Chen, WG [1 ]
Linsel-Nitschke, P [1 ]
Martinez, LO [1 ]
Agerholm-Larsen, B [1 ]
Silver, DL [1 ]
Tall, AR [1 ]
机构
[1] Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA
来源
JOURNAL OF CLINICAL INVESTIGATION | 2003年 / 111卷 / 01期
关键词
D O I
10.1172/JCI200316808
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cholesterol-loaded macrophage foam cells are a central component of atherosclerotic lesions. ABCA1, the defective molecule in Tangier disease, mediates the efflux of phospholipids and cholesterol from cells to apoA-1, reversing foam cell formation. In ABCA1, we identified a sequence rich in proline, glutamic acid, serine, and threonine (PEST sequence) that enhances the degradation of ABCA1 by calpain protease and thereby controls the cell surface concentration and cholesterol efflux activity of ABCA1. In an apparent positive feedback loop, apoA-1 binds ABCA1. promotes lipid efflux, inhibits calpain degradation, and leads to increased levels of ABCA1. ApoA-I infusion also increases ABCA1 in vivo. These studies reveal a novel mode of regulation of ABCA1 by PEST sequence-mediated calpain proteolysis that appears to be reversed by apolipoprotein-mediated phospholipid efflux. Inhibition of ABCA1 degradation by calpain could represent a novel therapeutic approach to increasing macrophage cholesterol efflux and decreasing atherosclerosis.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 50 条
  • [21] Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL
    Vassilis I. Zannis
    Angeliki Chroni
    Monty Krieger
    Journal of Molecular Medicine, 2006, 84 : 276 - 294
  • [22] Mutations in LCAT, ApoA-I, and ABCA1 can be distinguished by NMR lipoprotein subphenotyping
    Brownlie, A
    Hovingh, GK
    Coutinho, J
    Dube, MP
    Klerkx, AH
    Otvos, JD
    Ludwig, EH
    Kastelein, JJ
    Hayden, MR
    Kuivenhoven, JA
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) : E32 - E32
  • [23] ABCA1, apoE and apoA-I as potential therapeutic targets for treating Alzheimer's disease
    Namjoshi, Dhananjay
    Stukas, Sophie
    Wellington, Cheryl L.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2011, 1 (03) : 245 - 259
  • [24] CHARACTERIZATION OF APOA-I AND HDL METABOLISM IN AN ENDOTHELIAL SPECIFIC ABCA1 DEFICIENT MOUSE MODEL
    Hasballa, R.
    Rohrer, L.
    Fotakis, P.
    Zannis, V.
    Parks, J.
    von Eckardstein, A.
    ATHEROSCLEROSIS, 2015, 241 (01) : E43 - E43
  • [25] ABCA1, apoA-I, and BTn3A1: A Legitimate Menage a Trois in Dendritic Cells
    Riganti, Chiara
    Castella, Barbara
    Massaia, Massimo
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [26] Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL
    Mulya, Anny
    Lee, Ji-Young
    Gebre, Abraham K.
    Boudyguina, Elena Y.
    Chung, Soon-Kyu
    Smith, Thomas L.
    Colvin, Perry L.
    Jiang, Xian-Cheng
    Parks, John S.
    JOURNAL OF LIPID RESEARCH, 2008, 49 (11) : 2390 - 2401
  • [27] Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I
    Timmins, JM
    Lee, JY
    Boudyguina, E
    Kluckman, KD
    Brunham, LR
    Mulya, A
    Gebre, AK
    Coutinho, JM
    Colvin, PL
    Smith, TL
    Hayden, MR
    Maeda, N
    Parks, JS
    JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (05): : 1333 - 1342
  • [28] The Interaction of ApoA-I and ABCA1 Triggers Signal Transduction Pathways to Mediate Efflux of Cellular Lipids
    Zhao, Guo-Jun
    Yin, Kai
    Fu, Yu-chang
    Tang, Chao-Ke
    MOLECULAR MEDICINE, 2012, 18 (02) : 149 - 158
  • [29] HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney
    Lee, JY
    Timmins, JM
    Mulya, A
    Smith, TL
    Zhu, YW
    Rubin, EM
    Chisholm, JW
    Colvin, PL
    Parks, JS
    JOURNAL OF LIPID RESEARCH, 2005, 46 (10) : 2233 - 2245
  • [30] ABCA1 and atherosclerosis
    Soumian, S
    Albrecht, C
    Davies, AH
    Gibbs, RGJ
    VASCULAR MEDICINE, 2005, 10 (02) : 109 - 119